These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 1344660

  • 1. A reappraisal of the use of 5-methoxypsoralen in the therapy of psoriasis.
    Calzavara-Pinton P, Ortel B, Carlino A, Honigsmann H, De Panfilis G.
    Exp Dermatol; 1992 Jul; 1(1):46-51. PubMed ID: 1344660
    [Abstract] [Full Text] [Related]

  • 2. Bath-5-methoxypsoralen-UVA therapy for psoriasis.
    Calzavara-Pinton PG, Zane C, Carlino A, De Panfilis G.
    J Am Acad Dermatol; 1997 Jun; 36(6 Pt 1):945-9. PubMed ID: 9204060
    [Abstract] [Full Text] [Related]

  • 3. Treatment of psoriasis with a new micronized 5-methoxypsoralen tablet and UVA radiation.
    Aubin F, Makki S, Humbert P, Muret P, Agache P.
    Arch Dermatol Res; 1994 Jun; 286(1):30-4. PubMed ID: 8141609
    [Abstract] [Full Text] [Related]

  • 4. Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen.
    Berg M, Ros AM.
    Photodermatol Photoimmunol Photomed; 1994 Oct; 10(5):217-20. PubMed ID: 7880762
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of 8-methoxypsoralen vs. 5-methoxypsoralen plus ultraviolet A therapy in patients with mycosis fungoides.
    Wackernagel A, Hofer A, Legat F, Kerl H, Wolf P.
    Br J Dermatol; 2006 Mar; 154(3):519-23. PubMed ID: 16445785
    [Abstract] [Full Text] [Related]

  • 6. 5-Methoxypsoralen (Bergapten) in photochemotherapy of psoriasis.
    Hönigsmann H, Jaschke E, Gschnait F, Brenner W, Fritsch P, Wolff K.
    Br J Dermatol; 1979 Oct; 101(4):369-78. PubMed ID: 508604
    [Abstract] [Full Text] [Related]

  • 7. Photochemotherapy (PUVA) and psoriasis: comparison of 8-MOP and 8-MOP/5-MOP.
    Langner A, Wolska H, Kowalski J, Duralska H, Murawska E.
    Int J Dermatol; 1976 Nov; 15(9):688-9. PubMed ID: 977210
    [Abstract] [Full Text] [Related]

  • 8. Determination of 8-methoxypsoralen kinetics: a relevant factor in the treatment of psoriasis by psoralen plus ultraviolet A therapy.
    Bonnot D, Béani JC, Boitard M, Reymond JL, Bériel H, Amblard P.
    Photodermatol Photoimmunol Photomed; 1994 Feb; 10(1):33-7. PubMed ID: 8180098
    [Abstract] [Full Text] [Related]

  • 9. Kinetics and dose-response of photosensitivity in cream psoralen plus ultraviolet A photochemotherapy: comparative in vivo studies after topical application of three standard preparations.
    Grundmann-Kollmann M, Tegeder I, Ochsendorf FR, Zollner TM, Ludwig R, Kaufmann R, Podda M.
    Br J Dermatol; 2001 May; 144(5):991-5. PubMed ID: 11359386
    [Abstract] [Full Text] [Related]

  • 10. 5-Methoxypsoralen (Bergapten) for photochemotherapy. Bioavailability, phototoxicity, and clinical efficacy in psoriasis of a new drug preparation.
    Tanew A, Ortel B, Rappersberger K, Hönigsmann H.
    J Am Acad Dermatol; 1988 Feb; 18(2 Pt 1):333-8. PubMed ID: 3279089
    [Abstract] [Full Text] [Related]

  • 11. 5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo.
    McNeely W, Goa KL.
    Drugs; 1998 Oct; 56(4):667-90. PubMed ID: 9806110
    [Abstract] [Full Text] [Related]

  • 12. 5-Methoxy psoralen, etretinate, and UVA for psoriasis.
    Lane-Brown M.
    Int J Dermatol; 1987 Dec; 26(10):655-9. PubMed ID: 3429102
    [Abstract] [Full Text] [Related]

  • 13. Bath-water compared with oral delivery of 8-methoxypsoralen PUVA therapy for chronic plaque psoriasis.
    Collins P, Rogers S.
    Br J Dermatol; 1992 Oct; 127(4):392-5. PubMed ID: 1419760
    [Abstract] [Full Text] [Related]

  • 14. [Clinical experience with the 8-methoxypsoralen-UVA therapy (photochemotherapy) of psoriasis].
    Hofmann C, Plewig G, Braun-Falco O.
    Hautarzt; 1976 Dec; 27(12):588-94. PubMed ID: 1010746
    [Abstract] [Full Text] [Related]

  • 15. 8-MOP PUVA for psoriasis: a comparison of a minimal phototoxic dose-based regimen with a skin-type approach.
    Collins P, Wainwright NJ, Amorim I, Lakshmipathi T, Ferguson J.
    Br J Dermatol; 1996 Aug; 135(2):248-54. PubMed ID: 8881668
    [Abstract] [Full Text] [Related]

  • 16. Liquid formulations of 8-methoxypsoralen (8-MOP) and 5-MOP: a prospective double-blind crossover assessment of acute non-phototoxic adverse effects.
    George SA, Ferguson J.
    Photodermatol Photoimmunol Photomed; 1992 Feb; 9(1):33-5. PubMed ID: 1390121
    [Abstract] [Full Text] [Related]

  • 17. Cancer incidence among Finnish psoriasis patients treated with 8-methoxypsoralen bath PUVA.
    Hannuksela-Svahn A, Pukkala E, Koulu L, Jansén CT, Karvonen J.
    J Am Acad Dermatol; 1999 May; 40(5 Pt 1):694-6. PubMed ID: 10321595
    [Abstract] [Full Text] [Related]

  • 18. Narrow band UVB (311 nm) phototherapy and PUVA photochemotherapy: a combination.
    Calzavara-Pinton P.
    J Am Acad Dermatol; 1998 May; 38(5 Pt 1):687-90. PubMed ID: 9591811
    [Abstract] [Full Text] [Related]

  • 19. Systemic allergic contact dermatitis to 8-methoxypsoralen (8-MOP).
    Ravenscroft J, Goulden V, Wilkinson M.
    J Am Acad Dermatol; 2001 Dec; 45(6 Suppl):S218-9. PubMed ID: 11712064
    [Abstract] [Full Text] [Related]

  • 20. The relationship between plasma psoralen concentration and psoralen-UVA erythema.
    Mclelland J, Fisher C, Farr PM, Diffey BL, Cox NH.
    Br J Dermatol; 1991 Jun; 124(6):585-90. PubMed ID: 2064944
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.